MARIA CHERKASOVA

Dr. MARIA CHERKASOVA

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Tatiana Magomedalievna ReshetnyakTatiana Magomedalievna Reshetnyak
Tatiana Magomedalievna Reshetnyak
FCFariza Alanovna Cheldieva
Fariza Alanovna Cheldieva
MCMARIA CHERKASOVA
MARIA CHERKASOVA
ALAleksandr M Lila
Aleksandr M Lila
ENEvgeny Nasonov
Evgeny Nasonov
Objective: To define the role of IgA antibodies to cardiolipin (aCL) and IgA antibodies to beta-2 glycoprotein 1 (anti-β2-GP1) in the development of vascular complications in patients with antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE). Material and methods: A total of 187 patients with one of the following diagnoses: primary APS (PAPS), probable APS, SLE with APS, and SLE without APS. The comparison group consisted of 49 patients with other rheumatic diseases (RD), the control group included 100 relatively healthy individuals (without RD, oncological pathology, and infectious diseases). All patients underwent standard clinical, laboratory, and instrumental examinations before being included in the study and during follow-up. The aPL study included the determination of IgG/IgM aCL, IgG/IgM anti-β2-GP1 by enzyme-linked immunosorbent assay (ELISA), IgG/IgM/IgA aCL, IgG/IgM/IgA anti-β2-GP1 by chemiluminescence analysis (CLA), and lupus anticoagulant (LA). Results: IgA aCL were detected in 75 (40%) of the 187 patients with APS and SLE, in none of the comparison group, and in 2 (2%) of the control one. IgA anti-β2-GP1 were detected in 63 (34%) of the 187 patients with APS and SLE, in none of the patients in the comparison group, and in one (1%) of the control group. The prevalence of IgA aCL and IgA anti-β2-GP1 and their levels were statistically significantly higher in patients with APS (PAPS and SLE + APS) than the levels in patients with SLE and those of the comparison and control groups (p < 0.05). IgA aCL and IgA anti-β2-GP1 were significantly associated with thrombosis in APS (χ2 = 4.96; p = 0.02 and χ2 = 4.37; p = 0.04, respectively). The risk of thrombosis was 2.04 times higher in patients with positive IgA aCL than in patients without these antibodies, as well as in patients with positive IgA anti-β2-GP1; it was twice as high as in patients without antibodies. There was a high specificity of IgA aCL and IgA anti-β2-GP1 for both the diagnosis of APS and its clinical manifestations, despite a low sensitivity. Conclusions: The study revealed a relationship of thrombosis and APS with IgA aCL and IgA anti-β2-GP1. There was a high specificity of IgA aCL and IgA anti-β2-GP1 (95% and 93%, respectively) for the diagnosis of APS with a low sensitivity (54% and 44%, respectively). There were no patients with isolated positivity of IgA aCL and IgA anti-β2-GP1.

28 February 2022 in Rheumatology Science and Practice
Verified
Journal Article
Open access
PDF file
LAL. P. Ananyeva
L. P. Ananyeva
LGL. A. Garzanova
L. A. Garzanova
OKO. A. Koneva
O. A. Koneva
MSM. N. Starovoytova
M. N. Starovoytova
ODO. V. Desinova
O. V. Desinova
ENE. L. Nasonov
E. L. Nasonov
The aim of our study was to assess the relationship between the changes of antinuclear autoantibodies (ANA) and autoantibodies to topoisomerase 1 (anti-Topo 1) in systemic sclerosis (SSc) patients on rituximab (RTX) therapy.Materials and methods. The prospective study included 88 patients (73 women) with a mean age of 47 (17– 71) years. The mean disease duration was 5.9±4.8 years. The mean follow-up period was more than 2 years (27 (12–42) months).Results. We documented a statistically significant change in skin score, the disease activity index, improvement of pulmonary function and reduction of mean dose of prednisolone after RTX treatment. There was a significant decrease in the number of patients with high levels of ANA and overall decrease of the ANA and anti-Topo 1 levels. A moderate positive statistically significant correlation was found between ANA and anti-Topo 1 (r=0.403). In the group of patients positive for anti-Topo 1 there were a more pronounced depletion of B lymphocytes, significantly higher increase in forced vital capacity and diffusion capacity, decrease in the disease activity index, compared with a patients negative for anti-Topo 1.Conclusions. We observed the decline in the level of ANA and anti-Topo 1 in SSc patients after RTX therapy and it was correlated by an improvement of the main outcome parameters of the disease. Therefore, anti-Topo 1 positivity could be considered as a predictor of a better response to RTX treatment, especially in SSc patients with hyperproduction of anti-Topo 1.

12 October 2023 in Exploration of Immunology
Verified
Journal Article
Open access
PDF file
FCFariza Alanovna Cheldieva
Fariza Alanovna Cheldieva
Anastasiia A. ShumilovaAnastasiia A. Shumilova
Anastasiia A. Shumilova
MCMARIA CHERKASOVA
MARIA CHERKASOVA
SGSvetlana Glukhova
Svetlana Glukhova
ALAleksandr M Lila
Aleksandr M Lila
Tatiana Magomedalievna ReshetnyakTatiana Magomedalievna Reshetnyak
Tatiana Magomedalievna Reshetnyak
Aim: The study aims to evaluate the incidence of recurrent thromboses in patients with primary antiphospholipid syndrome (PAPS) and its association with the presence of different antiphospholipid antibodies (aPLs) and known thrombogenic risk factors. Methods: This retrospective study included 52 patients. The median age of the patients was 38.5 years [31.5; 43.5], and the duration of the disease was 9.0 years [3.1; 13.0]. aPLs, including IgG/IgM/IgA antibodies to cardiolipin (aCLs), IgG/IgM/IgA anti-beta2-glycoprotein I (anti-β2-GPI), IgG anti-domain I-β2-GPI (anti-β2-GPI DI) antibodies, IgG/IgM antibodies to the phosphatidylserine/prothrombin complex (aPS/PT), and other thrombosis risk factors were included for analysis. Results: Recurrent thrombosis was reported in 34 (65%) out of 52 patients and 18 (35%) did not have it. The main reason for the recurrence of thrombosis was the lack of anticoagulant therapy: in 18 (52.9%) out of 34 patients with recurrent thrombosis. Three patients were taking warfarin at the time of thrombosis recurrence, but target international normalized ratio (INR) levels were not achieved. Other patients with recurrent thrombosis were taking direct oral anticoagulants (DOACs). The risk of recurrent thrombotic events with positive IgG aCL was 10.33 (P = 0.002) and 21 (P = 0.007) times higher were examined in enzyme-linked immunoassay (ELISA) and chemiluminescent assay (CLA), respectively. The risk of thrombosis was 4.58 times higher in patients who were IgA aCL-positive (P = 0.01). Compared with other antibodies, with positive IgG values of anti-β2-GPI and IgG aPS/PT by ELISA, a lower probability of thrombosis recurrence was observed: 7.56 and 7.25, respectively. A high risk of recurrent thrombosis [odds ratio (OR) = 32.0] was observed in IgG anti-β2-GPI (CLA). The combination of IgG aCL with IgG anti-β2-GPI and with IgG anti-β2-GPIDI is more informative with respect to the risks of thrombosis recurrence compared to double positivity for aCL with anti-β2-GPI (OR = 20.71 vs. OR = 10.18). Triple positivity for IgG aCL with IgG anti-β2-GPI and with IgG aPS/PT also shows better results compared to positivity for aCL with anti-β2-GPI (OR = 6.06 vs. OR = 5.79). Among other risk factors, arterial hypertension (AH) and obesity were significant in relation to the recurrence of thrombosis. AH occurred in 22 (42%) of 52 patients with PAPS. AH was associated with recurrent thrombosis in PAPS patients: 18 (53%) out of 34 with recurrent thrombosis had AH versus 4 out of 18 without recurrent thrombosis (P = 0.003). Conclusions: Recurrent thrombosis in antiphospholipid syndrome (APS) is largely associated with IgG aCL, IgG anti-β2-GPI, IgG anti-β2-GPIDI, IgG aPS/PT, and IgA aCL positivity. AH was a significant risk factor for recurrent thrombosis.

10 July 2023 in Modern Rheumatology Journal
Verified
Journal Article
Open access
PDF file
SESh. F. Erdes
Sh. F. Erdes
KSK. V. Sakharova
K. V. Sakharova
TDT. V. Dubinina
T. V. Dubinina
MCMARIA CHERKASOVA
MARIA CHERKASOVA
The “Treat-to-target” (T2T) strategy for axial spondyloarthritis (axSpA) has made it possible to optimize therapy in most patients, but in some of them the treatment goals are not achieved.Objective: to analyze the clinical features of patients with ankylosing spondylitis (AS) with inefficacy of two or more biological disease modifying antirheumatic drugs (bDMARDs).Material and methods. From February 2020 to March 2022 458 patients with AS, who met the modified New York criteria of 1984, were admitted to V.A. Nasonova Research Institute of Rheumatology. From this group, 30 (6.6%) patients with high clinical disease activity and inefficacy of at least two bDMARDs were selected. The control group consisted of 139 (30.5%) patients with AS, who either had no history of bDMARDs use, or had previously received only one of them. All patients were examined in accordance with generally accepted methods and underwent a double expert control.Results and discussion. Men predominated in the main and control groups (67 and 60%, respectively). In patients of the main group, there was a higher laboratory activity of the disease, especially ESR (p=0.002), more often peripheral arthritis was detected. In both groups, there was a high incidence of coxitis (69.2 and 69.7%, respectively), while in the main group there were significantly more patients who underwent total joint arthroplasty, and the frequency of detected syndesmophytes was 2 times lower compared to the control. Differences in the features of AS onset were also established: in the main group, the disease often began with reactive arthritis (ReA), while in the control group, with inflammatory back pain.Conclusion. The T2T strategy in axSpA does not always lead to the achievement of the intended goals, and, according to our data, among inpatients with AS, the number of people with a history of inefficacy of two or more bDMARDs reaches 6%. In these patients, compared with the control, the following features of the disease can be distinguished: frequent onset with ReA, a significant incidence of peripheral arthritis and joint arthroplasty, and a higher ESR.

27 December 2024 in Rheumatology Science and Practice
Verified
Journal Article
Open access
PDF file
TPTaras Panevin
Taras Panevin
TKT. V. Korotaeva
T. V. Korotaeva
SESh. F. Erdes
Sh. F. Erdes
RRR. V. Rozhivanov
R. V. Rozhivanov
EZE. G. Zotkin
E. G. Zotkin
MCMARIA CHERKASOVA
MARIA CHERKASOVA
The aim – to study the incidence of hypogonadism in men with psoriatic arthritis (PsA) and to assess its impact on PsA and comorbidities.Materials and methods. A cross-sectional continuous study included 128 men with PsA who were hospitalized at the V.A. Nasonova Research Institute of Rheumatology. The patients underwent determination of their total testosterone levels and subsequent division into subgroups with normal (≥12.0 nmol/l) and reduced levels. An intergroup comparison was conducted for the main indicators used in clinical rheumatology practice to assess the stage, activity, and other medical and demographic characteristics of PsA, as well as for comorbidities. A correlation analysis was performed between the level of total testosterone and some clinical and laboratory parameters.Results. The incidence of reduced total testosterone levels was 36.7%. Patients with testosterone deficiency were older (47.9±10.3 vs 40.1±12.1 years; p<0.001), had a higher body mass index (31.2±5.2 vs 27.2±6.1 kg/m2; p<0.001) and were more often obese (48.9% vs 23.4%; p=0.001). They had higher mean glucose levels (5.9±1.39 vs 5.34±0.57 mmol/l; p=0.001) and frequency of impaired fasting glycemia with similar frequency of type 2 diabetes mellitus. Patients with hypogonadism were characterized by higher uric acid levels (402.9±99.3 vs 354.0±81.5 μmol/L; p=0.003) and the frequency of hyperuricemia. A lower proportion of HLA-B27 positive patients was noted in the hypogonadism group, as well as a more frequent occurrence of stage III sacroiliitis (p=0.004) and a smaller amplitude of lateral flexion in the spine (10.3±3.3 vs 12.4±4.3 cm; p=0.014). Significant negative relationships were found between total testosterone levels and age, body mass index, glucose and uric acid levels, as well as a positive relationship with the amplitude of lateral flexion and chest excursion.Conclusion. Hypogonadism was detected in one third of patients with PsA. Decreased testosterone levels were observed in older individuals and were associated with metabolic disorders, as well as with decreased spinal mobility and the presence of stage III of sacroiliitis.

21 August 2024 in Modern Rheumatology Journal
Verified
Journal Article
Open access
PDF file
ЕВЕ. Н. Воркель
Е. Н. Воркель
Tatiana Magomedalievna ReshetnyakTatiana Magomedalievna Reshetnyak
Tatiana Magomedalievna Reshetnyak
KNK. S. Nurbaeva
K. S. Nurbaeva
MCMARIA CHERKASOVA
MARIA CHERKASOVA
GTG. M. Tarasova
G. M. Tarasova
ALAleksandr M Lila
Aleksandr M Lila
Antineutrophil cytoplasmic antibody-associated systemic vasculitis (ANCA-SV) is a group of rare and potentially severe systemic diseases. The search for reliable methods to assess ANCA-SV activity remains relevant. Among the indicators of neutrophil activation that have emerged in clinical practice, the level of serum calprotectin (CLP) stands out, which can be a marker for monitoring vasculitis activity and identifying patients at risk of disease relapse. Objective: to determine serum CLP levels in patients with ANCA-SV. Material and methods. The study group comprised 64 patients (37 with granulomatosis with polyangiitis, 11 with eosinophilic granulomatosis with polyangiitis and 16 with microscopic polyangiitis) aged 18 years and older with a confirmed diagnosis of ANCA-SV. The control group consisted of 30 healthy individuals. ANCA-SV activity was determined using the BVAS index; high activity corresponded to a BVAS value of >3. Damage was assessed using the VDI index. Depending on ANCA-SV activity, patients were divided into two groups: high activity group (group 1, n=33) and low activity group (group 2, n=31). In addition to the generally accepted indicators, serum CLP levels were assessed in all patients with ANCA-SV and healthy donors. Results and discussion. Statistically significant differences (p<0.001) were found in CLP levels in patients with ANCA-SV in groups 1 and 2. A significant correlation was found between CLP concentration and leukocyte count, neutrophil count, neutrophil-to-lymphocyte ratio (NLR) and systemic inflammatory index (SII). Blood CLP levels in ANCA-SV were associated with creatinine levels and not with glomerular filtration rate and urinary sediment. Although CLP concentration depended on disease activity, it did not correlate with acute phase indicators, including ESR and CRP concentration. Conclusion. Serum CLP concentration is significantly higher in patients with active ANCA-SV and is related to NLR and SII inflammatory indices, so we consider the possibility of using this indicator to assess disease activity.